MA41291A - Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer - Google Patents
Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancerInfo
- Publication number
- MA41291A MA41291A MA041291A MA41291A MA41291A MA 41291 A MA41291 A MA 41291A MA 041291 A MA041291 A MA 041291A MA 41291 A MA41291 A MA 41291A MA 41291 A MA41291 A MA 41291A
- Authority
- MA
- Morocco
- Prior art keywords
- ubique
- pyrrolotriazinone
- usp7
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical class O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- BEBRHYJBTAMGRW-UHFFFAOYSA-N pyrrolo[3,2-d]triazin-4-one Chemical compound O=C1N=NN=C2C=CN=C12 BEBRHYJBTAMGRW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098145P | 2014-12-30 | 2014-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41291A true MA41291A (fr) | 2017-11-07 |
Family
ID=55272609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041291A MA41291A (fr) | 2014-12-30 | 2015-12-28 | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000495B2 (fr) |
| EP (1) | EP3240790A1 (fr) |
| JP (1) | JP2018500377A (fr) |
| HK (1) | HK1246285A1 (fr) |
| MA (1) | MA41291A (fr) |
| WO (1) | WO2016109480A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| WO2016126935A1 (fr) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 |
| US9932351B2 (en) | 2015-02-05 | 2018-04-03 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GEAP202014982A (en) | 2016-06-10 | 2020-06-10 | Servier Lab | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
| WO2018009812A1 (fr) | 2016-07-08 | 2018-01-11 | Mayo Foundation For Medical Education And Research | Procédés et matériaux de traitement du cancer |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AU2018377976A1 (en) | 2017-11-29 | 2020-06-04 | Les Laboratoires Servier | New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7 |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| EP3870179A4 (fr) | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | Inhibition d'usp7 |
| BR112021008255A2 (pt) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | compostos de 6-azabenzimidazol substituídos como inibidores de hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| SG11202105913RA (en) * | 2018-12-06 | 2021-07-29 | Almac Discovery Ltd | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) |
| US20220125760A1 (en) | 2019-02-14 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml) |
| WO2020207352A1 (fr) * | 2019-04-11 | 2020-10-15 | 四川科伦博泰生物医药股份有限公司 | Composés de benzimidazole triazine et leur utilisation médicale |
| EP3965749A4 (fr) * | 2019-05-06 | 2023-06-21 | Valo Health, Inc. | Inhibition de l'usp19 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| CA3167473A1 (fr) * | 2020-02-28 | 2021-09-02 | Immunologik Gmbh | Inhibiteurs de desubiquitinases humaines pour le traitement d'infections coronavirales |
| CN113801135B (zh) * | 2020-06-15 | 2025-06-24 | 四川科伦博泰生物医药股份有限公司 | 噻吩并吡唑类化合物，包含其的药物组合物及其用途 |
| AU2022315201A1 (en) * | 2021-07-20 | 2024-01-18 | Dana-Farber Cancer Institute, Inc. | Inhibitors targeting ubiquitin specific protease 7 (usp7) |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5985863A (en) | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
| US6008217A (en) | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| IN151496B (fr) | 1980-02-26 | 1983-05-07 | Chamanlal Jagannath Shishoo | |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JPH02163569A (ja) | 1988-12-14 | 1990-06-22 | Nippon Piston Ring Co Ltd | ピストンリングの計測方法及び装置 |
| JP2777159B2 (ja) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
| US5124335A (en) | 1991-01-30 | 1992-06-23 | Merck & Co., Inc. | Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US20120165319A1 (en) | 1995-12-20 | 2012-06-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1 beta converting enzyme |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| CA2288735A1 (fr) | 1997-05-08 | 1998-11-12 | Agrevo Uk Limited | Fongicides |
| US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
| EP1073643B1 (fr) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant |
| NL1011737C2 (nl) | 1999-04-06 | 2000-10-09 | Ct For Immunopharmacology | Verbinding voor het remmen van de influx van polymorphonucleaire leukocyten (PMNs) in een weefsel, werkwijze voor het selecteren van een dergelijke verbinding, een farmaceutisch preparaat en een toepassing van de verbinding. |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US20060183776A9 (en) | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| ATE345803T1 (de) | 2000-03-03 | 2006-12-15 | Eisai Co Ltd | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| US20030153598A1 (en) | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| EP1286997B1 (fr) | 2000-06-07 | 2004-08-18 | Almirall Prodesfarma, S.A. | Derives de 6-phenyl-pyrrolo-pyrimidinedione |
| JP2004501918A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Ｘａ因子阻害剤としての１−（ヘテロアリール−フェニル）−縮合ピラゾール誘導体 |
| JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
| PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| US20020169175A1 (en) | 2001-02-05 | 2002-11-14 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of heterocyclic compounds |
| US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
| WO2003024456A1 (fr) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methodes de traitement et de prevention des migraines |
| AU2002340232A1 (en) | 2001-10-17 | 2003-04-28 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| IL164005A0 (en) | 2002-03-13 | 2005-12-18 | Janssen Pharmaceutica Nv | Carbonylamino-derivatives as novel inhibitiors of histone deacetylase |
| GB2405336A (en) | 2002-05-01 | 2005-03-02 | Eisai Co Ltd | Cholinesterase inhibitors to prevent injuries caused by chemicals |
| AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| WO2004014908A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloproteinases heterobicycliques |
| WO2004014916A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs bicycliques condenses de metalloproteinases de type pyrimidine |
| US20040132732A1 (en) | 2002-10-21 | 2004-07-08 | Wei Han | Quinazolinones and derivatives thereof as factor Xa inhibitors |
| WO2004058727A1 (fr) | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite |
| ES2289377T3 (es) | 2003-03-18 | 2008-02-01 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Nuevas pirazolopirimidonas y su uso como inhibidores de pde. |
| EP1646615B1 (fr) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp |
| US7557113B2 (en) | 2003-08-26 | 2009-07-07 | Teijin Pharma Limited | Substituted pyrrolo[3,2-d]pyrimidine derivatives |
| CA2536887C (fr) | 2003-08-26 | 2012-03-06 | Teijin Pharma Limited | Derive de pyrrolopyrimidinone |
| US20050187147A1 (en) | 2003-09-22 | 2005-08-25 | Newman Michael J. | Compositions and methods for increasing drug efficiency |
| US20050148534A1 (en) | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| WO2005030704A1 (fr) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibiteurs d'histone deacetylase |
| US20080312189A1 (en) | 2004-03-05 | 2008-12-18 | Eisai Co., Ltd. | Cadasil Treatment with Cholinesterase Inhibitors |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| NZ551004A (en) | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
| US20080045500A1 (en) | 2004-07-01 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Nerve Regeneration Stimulator |
| US20060172992A1 (en) | 2004-08-13 | 2006-08-03 | Eisai Co., Ltd. | Therapeutic agent for overactive bladder resulting from cerebral infarction |
| US20060135507A1 (en) | 2004-08-13 | 2006-06-22 | Osamu Yokoyama | Therapeutic agent for overactive bladder involved in aging |
| NZ553087A (en) | 2004-08-31 | 2010-12-24 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-raf inhibitors |
| US20080064680A1 (en) | 2004-09-14 | 2008-03-13 | Bamdad Cynthia C | Methods for Diagnosis and Treatment of Cancer |
| JP2006176503A (ja) | 2004-11-26 | 2006-07-06 | Tohoku Univ | 脳血管障害を伴うアルツハイマー病治療薬 |
| JPWO2006068163A1 (ja) | 2004-12-24 | 2008-06-12 | 大日本住友製薬株式会社 | 二環性ピロール誘導体 |
| JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US7745447B2 (en) | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
| US20090192138A1 (en) | 2005-12-23 | 2009-07-30 | Daniel Kaspar Baeschlin | compounds |
| WO2008024978A2 (fr) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Dérivés de benzène, de pyridine et de pyridazine |
| CL2008000252A1 (es) | 2007-01-29 | 2008-03-14 | Xenon Pharmaceuticals Inc | Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir |
| CN101686952A (zh) | 2007-03-12 | 2010-03-31 | Vm生物医药公司 | 新型钙离子通道调节剂 |
| CN101730703B (zh) | 2007-03-16 | 2012-12-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂 |
| US20100184706A1 (en) | 2007-03-20 | 2010-07-22 | Bachovchin William W | Fap-activated chemotherapeutic compounds, and methods of use thereof |
| CA2685753A1 (fr) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Derives bicycliques de pyrimidine en tant que bloqueurs des canaux calciques |
| RU2345996C1 (ru) | 2007-07-17 | 2009-02-10 | Андрей Александрович Иващенко | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения |
| RU2341527C1 (ru) | 2007-07-17 | 2008-12-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ |
| CA2706018C (fr) | 2007-11-30 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Derives de 1,5-dihydro-pyrazolo(3,4-d)pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a pour le traitement de troubles du snc |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CA2719362A1 (fr) | 2008-04-04 | 2009-10-08 | Gilead Sciences, Inc. | Derives de pyrrolotriazinone pouvant etre utilises a titre d'inhibiteurs de stearoyl-coa desaturase |
| AU2009282480B2 (en) | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| US20110082158A1 (en) | 2008-10-01 | 2011-04-07 | Aleem Gangjee | Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same |
| WO2010075561A1 (fr) | 2008-12-23 | 2010-07-01 | President And Fellows Of Harvard College | Inhibiteurs de la nécroptose de petite taille moléculaire |
| CN102438624B (zh) | 2009-03-13 | 2016-03-30 | 阿德维纳斯治疗私人有限公司 | 取代的稠合嘧啶化合物 |
| WO2011024873A1 (fr) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | Dérivé d'hétérocycle condensé et son utilisation |
| BR112012008518A2 (pt) | 2009-10-13 | 2016-04-05 | Msd Oss Bv | derivado heterocíclico, e, composição farmacêutica |
| KR101590764B1 (ko) | 2009-11-13 | 2016-02-02 | 삼성전자주식회사 | 컴퓨팅 시스템 및 컴퓨팅 시스템의 메모리 관리 방법 |
| US20130085133A1 (en) | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
| US8575114B2 (en) | 2010-03-23 | 2013-11-05 | Albany Molecular Research, Inc. | SGLT-2 inhibitors, methods of making them, and uses thereof |
| WO2012054332A1 (fr) | 2010-10-18 | 2012-04-26 | Millennium Pharmaceuticals, Inc. | Acides hydroxamiques substitués et leurs utilisations |
| WO2012075393A2 (fr) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activateurs de la dégradation protéasomique et leurs utilisations |
| WO2012096928A2 (fr) | 2011-01-10 | 2012-07-19 | Glaxosmithkline Llc | Dérivés de pyrimidinone en tant qu'inhibiteurs de l'acide gras synthase |
| GB201107768D0 (en) | 2011-05-10 | 2011-06-22 | Univ Manchester | Riboswitches |
| EP2565186A1 (fr) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| TW201348226A (zh) | 2012-02-28 | 2013-12-01 | Amgen Inc | 作為ｐｉｍ抑制劑之醯胺 |
| GB201205164D0 (en) | 2012-03-23 | 2012-05-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP2016504365A (ja) * | 2012-12-28 | 2016-02-12 | アメリカ合衆国 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
| KR101446680B1 (ko) | 2013-02-08 | 2014-10-07 | 한국과학기술연구원 | ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체 |
| CN103833646A (zh) | 2014-02-28 | 2014-06-04 | 广东工业大学 | 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用 |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| US9932351B2 (en) | 2015-02-05 | 2018-04-03 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| WO2016126935A1 (fr) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7 |
-
2015
- 2015-12-28 MA MA041291A patent/MA41291A/fr unknown
- 2015-12-29 EP EP15830954.2A patent/EP3240790A1/fr not_active Withdrawn
- 2015-12-29 JP JP2017535009A patent/JP2018500377A/ja active Pending
- 2015-12-29 US US14/982,131 patent/US10000495B2/en active Active
- 2015-12-29 HK HK18105708.2A patent/HK1246285A1/zh unknown
- 2015-12-29 WO PCT/US2015/067781 patent/WO2016109480A1/fr not_active Ceased
-
2018
- 2018-05-24 US US15/988,790 patent/US10351571B2/en active Active
-
2019
- 2019-06-24 US US16/449,599 patent/US10981915B2/en active Active
-
2021
- 2021-04-14 US US17/230,603 patent/US11795171B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018500377A (ja) | 2018-01-11 |
| US10000495B2 (en) | 2018-06-19 |
| HK1246285A1 (zh) | 2018-09-07 |
| EP3240790A1 (fr) | 2017-11-08 |
| US11795171B2 (en) | 2023-10-24 |
| US20160185786A1 (en) | 2016-06-30 |
| US20180339991A1 (en) | 2018-11-29 |
| WO2016109480A1 (fr) | 2016-07-07 |
| WO2016109480A8 (fr) | 2016-10-27 |
| US10351571B2 (en) | 2019-07-16 |
| US20190308980A1 (en) | 2019-10-10 |
| US20220033403A1 (en) | 2022-02-03 |
| US10981915B2 (en) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41291A (fr) | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer | |
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA45406A (fr) | Inhibiteurs d'ezh2 pour traiter le cancer | |
| JO3512B1 (ar) | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | |
| EP3368559A4 (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3400011A4 (fr) | Combinaisons anti-cd20 pour le traitement des tumeurs | |
| EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA49841A (fr) | Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine | |
| EP3443962A4 (fr) | Dérivé de quinoline pour le traitement du cancer de l'estomac | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| EP3353204A4 (fr) | Méthodes et compositions pour le traitement du cancer |